Business
OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules
OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules Nantes, June 20th, 2025, 7:30 p.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), publishes a “Questions and Answers” document for all its shareholders and informs the market of ongoing procedures, in line with its commitment to holding the annual General Meeting with transparency, serene debates, and compliance with market rules. In line with its continu
About this update from Ose Immunotherapeutics Sa
[{"type":"image","alt":"OSE Immunotherapeutics","displaySize":"","headline":null,"caption":"OSE Immunotherapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/h55Oot7mWh39J7Yvj1GueA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb","width":300,"height":100}},"lazy":false},{"type":"text","content":"OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules","length":127,"tagName":"p"},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"text","content":"Nantes, June 20th, 2025, 7:30 p.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), publishes a “Questions and Answers” document for all its shareholders and informs the market of ongoing procedures, in line with its commitment to holding the annual General Meeting with transparency, serene debates, and compliance with market rules.","length":347,"tagName":"p"},{"type":"text","content":"In line with its continuous information and transparency approach towards shareholders, the Company has published a "Questions and Answers" document, accessible at the following address: https://www.ose-immuno.com/wp-content/uploads/2025/06/EN_QA_June20_2026.pdf, intended to answer the main questions of shareholders regarding recent events.","length":352,"tagName":"p"},{"type":"text","content":"Nicolas Poirier, CEO of OSE, states: "We have a responsibility to all those who expect seriousness and results from OSE, primarily the patients. We cannot leave the false information communicated to the market unanswered. For example, there is no plan to use venture debt instruments. In response to these unfounded rumors, we have decided to publish this "Questions and Answers" document. An exchange with all shareholders will be organized soon in the same spirit."","length":487,"tagName":"p"},{"type":"text","content":"Following the declaration of a concerted action and the submission of several resolutions aimed at significantly altering the composition of the Board of Directors by a group of shareholders1, the Company reminds the market, that it had reques...